Risk stratification systems have been developed by various cancer and urological organizations such as the National Comprehensive Cancer Network (NCCN, USA), National Institute for Health and Clinical Excellence (NICE, UK), European Society of Medical Oncology (ESMO), American Urological Association (AUA), and the European Association of Urology (EAU), which are risk stratifying patients by grade group and their serum prostate-specific antigen levels (PSA) into low-risk to very high-risk, with staging imaging indicated for patients with an unfavourable-intermediate risk and above [1,4,5]. Here, KLK3 is linked to cancer.